MX2017011978A - Analogos deuterados de etifoxina, sus derivados y usos de estos. - Google Patents

Analogos deuterados de etifoxina, sus derivados y usos de estos.

Info

Publication number
MX2017011978A
MX2017011978A MX2017011978A MX2017011978A MX2017011978A MX 2017011978 A MX2017011978 A MX 2017011978A MX 2017011978 A MX2017011978 A MX 2017011978A MX 2017011978 A MX2017011978 A MX 2017011978A MX 2017011978 A MX2017011978 A MX 2017011978A
Authority
MX
Mexico
Prior art keywords
etifoxine
deuterated analogs
derivatives
preparation
methods
Prior art date
Application number
MX2017011978A
Other languages
English (en)
Other versions
MX383647B (es
Inventor
Dasse Olivier
Original Assignee
Anvyl Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anvyl Llc filed Critical Anvyl Llc
Publication of MX2017011978A publication Critical patent/MX2017011978A/es
Publication of MX383647B publication Critical patent/MX383647B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Esta invención se refiere a análogos deuterados de etifoxina de la Fórmula I, solvatos, profármacos, y sales farmacéuticamente aceptables de estos, así como a métodos para su preparación y uso, y a composiciones farmacéuticas. (Ver fórmula).
MX2017011978A 2015-03-20 2016-03-18 Análogos deuterados de etifoxina, sus derivados y usos de estos. MX383647B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135979P 2015-03-20 2015-03-20
PCT/US2016/023231 WO2016154039A1 (en) 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof

Publications (2)

Publication Number Publication Date
MX2017011978A true MX2017011978A (es) 2018-02-09
MX383647B MX383647B (es) 2025-03-14

Family

ID=56977741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011978A MX383647B (es) 2015-03-20 2016-03-18 Análogos deuterados de etifoxina, sus derivados y usos de estos.

Country Status (21)

Country Link
US (4) US10080755B2 (es)
EP (1) EP3347006B1 (es)
JP (3) JP6762507B2 (es)
KR (1) KR102290766B1 (es)
CN (1) CN107530323B (es)
AU (2) AU2016235495B2 (es)
BR (1) BR112017020081B1 (es)
CA (1) CA2979853C (es)
DK (1) DK3347006T3 (es)
ES (1) ES2928396T3 (es)
HR (1) HRP20221240T1 (es)
HU (1) HUE060240T2 (es)
IL (2) IL270627B2 (es)
LT (1) LT3347006T (es)
MX (1) MX383647B (es)
PL (1) PL3347006T3 (es)
PT (1) PT3347006T (es)
RS (1) RS63654B1 (es)
SI (1) SI3347006T1 (es)
SM (1) SMT202200407T1 (es)
WO (1) WO2016154039A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102290766B1 (ko) * 2015-03-20 2021-08-19 가바 테라퓨틱스, 아이엔씨. 에티폭신의 중수소화 유사체, 이의 유도체 및 그의 용도
US10420773B2 (en) * 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
AU2019239096A1 (en) * 2018-03-23 2020-08-27 Concert Pharmaceuticals, Inc. Deuterated analogs of D-beta-hydroxybutyric acid and uses thereof
CA3100716A1 (en) * 2018-05-18 2019-11-21 Ovid Therapeutics Inc. Methods of treating attention deficit hyperactivity disorder
CN112125862A (zh) * 2019-06-25 2020-12-25 上海安谱实验科技股份有限公司 一种稳定同位素标记的阿特拉津-d5及其合成方法
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
KR20240050372A (ko) * 2021-09-14 2024-04-18 난징 미노바 파마슈티컬 컴퍼니, 리미티드 수용성 알로프레그나놀론 유도체 및 이의 제조 방법과 용도
WO2023218251A1 (en) * 2022-05-10 2023-11-16 Clearsynth Labs Limied Novel deuterium-enriched nefazodone analogues and method for preparing thereof
CN120390643A (zh) * 2022-10-24 2025-07-29 加巴疗法股份有限公司 艾替伏辛的氘代类似物及施用而没有代谢自身诱导的方法
WO2025085958A1 (en) * 2023-10-23 2025-05-01 Glomesh Intl Pty Ltd A module for mounting items

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670772C3 (de) 1966-11-24 1978-04-20 Hoechst Ag, 6000 Frankfurt 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
FR2888748B1 (fr) * 2005-07-19 2007-10-12 Biocodex Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
US20080039453A1 (en) * 2006-03-20 2008-02-14 David Putman Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2007109289A1 (en) 2006-03-20 2007-09-27 Xytis Inc. Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
JP2011001308A (ja) * 2009-06-19 2011-01-06 Research Foundation Itsuu Laboratory 重水素化カルボスチリル化合物
WO2012006538A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2013005753A1 (ja) * 2011-07-05 2013-01-10 公益財団法人乙卯研究所 重水素化フェニルプロピオン酸誘導体
FR3016881B1 (fr) 2014-01-29 2016-03-04 Biocodex Traitement des degenerescences et des lesions photo-induites de la retine
KR102290766B1 (ko) * 2015-03-20 2021-08-19 가바 테라퓨틱스, 아이엔씨. 에티폭신의 중수소화 유사체, 이의 유도체 및 그의 용도

Also Published As

Publication number Publication date
KR20170137085A (ko) 2017-12-12
US10736901B2 (en) 2020-08-11
JP2023009114A (ja) 2023-01-19
IL270627A (es) 2019-12-31
US11672805B2 (en) 2023-06-13
JP7376668B2 (ja) 2023-11-08
US20230263805A1 (en) 2023-08-24
HRP20221240T1 (hr) 2022-12-09
EP3347006A4 (en) 2019-04-24
PT3347006T (pt) 2022-10-17
SMT202200407T1 (it) 2022-11-18
US20190015419A1 (en) 2019-01-17
US20200405726A1 (en) 2020-12-31
AU2020201728B2 (en) 2021-12-23
CA2979853A1 (en) 2016-09-29
US20180064717A1 (en) 2018-03-08
CN107530323A (zh) 2018-01-02
EP3347006B1 (en) 2022-07-27
JP6762507B2 (ja) 2020-09-30
EP3347006A1 (en) 2018-07-18
US12433896B2 (en) 2025-10-07
AU2016235495A1 (en) 2017-10-05
PL3347006T3 (pl) 2022-11-14
JP2021001174A (ja) 2021-01-07
JP2018508592A (ja) 2018-03-29
CA2979853C (en) 2021-05-11
AU2016235495B2 (en) 2020-05-14
DK3347006T3 (da) 2022-10-17
IL270627B2 (en) 2023-03-01
BR112017020081A2 (pt) 2018-06-05
IL270627B (en) 2022-11-01
ES2928396T3 (es) 2022-11-17
LT3347006T (lt) 2022-10-25
RS63654B1 (sr) 2022-11-30
WO2016154039A1 (en) 2016-09-29
IL254567A0 (en) 2017-11-30
IL254567B (en) 2020-03-31
MX383647B (es) 2025-03-14
KR102290766B1 (ko) 2021-08-19
US10080755B2 (en) 2018-09-25
BR112017020081B1 (pt) 2021-11-30
AU2020201728A1 (en) 2020-03-26
HUE060240T2 (hu) 2023-02-28
SI3347006T1 (sl) 2022-11-30
CN107530323B (zh) 2021-05-04

Similar Documents

Publication Publication Date Title
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
PH12016501440A1 (en) Novel heterocyclic compounds
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CR20190566A (es) Inhibidores de quinasay usos de los mismos
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
ECSP17069696A (es) Compuestos novedosos
MX376283B (es) Compuestos de imidazopiridazina.
TR201819805T4 (tr) Flavaglin türevleri̇.
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
MX2020005336A (es) Analogos de d-serina deuterados y usos de los mismos.
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda